Stock CESSA CESSATECH A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 03:30:00 03/05/2024 am IST 		5-day change 1st Jan Change
6.12 DKK +0.33% Intraday chart for Cessatech A/S -7.55% -15.70%
29/02 Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
A short business update
AQ
Minutes from the Annual General Meeting in Cessatech A/S
AQ
Annual General Meeting - 27 March 2024
AQ
Cessatech A/S publishes Annual Report for the fiscal year 2023
AQ
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023
CI
CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2
AQ
LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024
AQ
CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2
AQ
CESSATECH ANNOUNCES THE START OF THE EXERCISE PERIOD FOR WARRANTS OF SERIES TO2
AQ
CESSATECH ANNOUNCES TO2 WARRANT EXERCISE PRICE AND START OF EXERCISE PERIOD
AQ
Q&A session related topline data Study 0205
AQ
Cessatech: Cessatech announces positive topline data from study 0205 with its lead candidate CT001 for the treatment of pain in children supporting further advancement of CT001
PU
Third Quarter Report Q3-2023
AQ
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children
AQ
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children
CI
Cessatech announces last participant dosed in pivotal trial 0205 with lead candidate CT001
AQ
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001
CI
Cessatech Wins EU Nod for Clinical Studies of Nasal Sedation Spray in Children; Shares Soar 21%
MT
Cessatech announces agreement with the European Medicines Agency on a Paediatric Investigational Plan for its second asset CT002 for medical procedural sedation in children
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CESSA Stock
  4. News Cessatech A/S